科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery2026-06-15

Outcomes of sleeve gastrectomy and Roux-en-Y gastric bypass in patients with liver disease and body mass index ≥ 40: analysis using the 2023 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program database.

Raul Sebastian, Alba Zevallos, Oscar Tuesta, Adrian Riva, Jessica Biller, Gina Adrales, Christina Li, Michael Schweitzer

一句话结论 · In one sentence

Bariatric surgery in patients with liver disease is safe and feasible with similar mortality and cardiopulmonary complications compared to patients without liver disease. However, patients with liver disease have a higher rate of complications, including emergency visits, SSI, readmissions, and blood transfusions after bariatric surgery. Furthermore, patients with liver disease and BMI ≥40 have higher rates of unplanned intensive care unit admission, emergency visits, readmissions, and reoperations.

原始摘要(英文原文)· Original abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD), prevalent in bariatric surgery patients, is a leading indication for liver transplantation. However, class III obesity is a relative contraindication for transplantation. OBJECTIVE: To evaluate the safety of bariatric surgery in patients with mild to moderate liver disease of any cause. SETTING: 2023 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database. METHODS: Patients who underwent sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) were included. We performed a 1:1 propensity score matching analysis with 27 preoperative characteristics. We compared 30-day postoperative outcomes for patients with body mass index (BMI) < 40 with versus without liver disease after SG (Analysis 1) or RYGB (Analysis 2) and for patients with BMI ≥ 40 with versus without liver disease after SG (Analysis 3) or RYGB (Analysis 4). RESULTS: From 182,673 patients (71% SG; 29% RYGB), outcomes in analysis 1 showed that patients with liver disease are associated with higher rates of surgical site infection (SSI), and blood transfusions (P < .05). Analysis 2 showed that patients with liver disease are associated with higher rates of emergency visits, readmissions, reoperations, and SSI (P < .05). In analysis 3, patients with liver disease had higher rates of unplanned intensive care unit admission, emergency visits, SSI, blood transfusions, and readmissions (P < .05). In analysis 4, patients with liver disease had higher rates of emergency visits and SSI (P < .05). However, there were no differences across the four analyses in mortality and cardiopulmonary complications. CONCLUSION: Bariatric surgery in patients with liver disease is safe and feasible with similar mortality and cardiopulmonary complications compared to patients without liver disease. However, patients with liver disease have a higher rate of complications, including emergency visits, SSI, readmissions, and blood transfusions after bariatric surgery. Furthermore, patients with liver disease and BMI ≥40 have higher rates of unplanned intensive care unit admission, emergency visits, readmissions, and reoperations.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Outcomes of sleeve gastrectomy and Roux-en-Y gastric bypass in patients with liver disease and body mass index ≥ 40: analysis using the 2023 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program database. — 科研速览 Science Skim